References
- S. Moncada and E.A. Higgs, Endogenous nitric oxide: Physiology, pathology and clinical relevance, Eur. J. Clin. Investig. 21 (1991), pp. 361–374. doi:https://doi.org/10.1111/j.1365-2362.1991.tb01383.x.
- M. Rosselli, P.J. Keller, and R.K. Dubey, Role of nitric oxide in the biology, physiology and pathophysiology of reproduction, Hum. Reprod. Update 4 (1998), pp. 3–24. doi:https://doi.org/10.1093/humupd/4.1.3.
- S. Moncada, Nitric oxide: Discovery and impact on clinical medicine, J. R. Soc. Med. 92 (1999), pp. 164–169. doi:https://doi.org/10.1177/014107689909200402.
- S. Moncada and E.A. Higgs, The discovery of nitric oxide and its role in vascular biology, Br. J. Pharmacol. 147 (2006), pp. S193–S201. doi:https://doi.org/10.1038/sj.bjp.0706458.
- K.E. Andersson, PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery, Br. J. Pharmacol. 175 (2018), pp. 2554–2565. doi:https://doi.org/10.1111/bph.14205.
- J.B. Hibbs, Synthesis of nitric oxide from L-arginine: A recently discovered pathway induced by cytokines with antitumor and antimicrobial activity, Res. Immunol. 142 (1991), pp. 565–569. doi:https://doi.org/10.1016/0923-2494(91)90103-p.
- M. Aoyagi, A.S. Arvai, J.A. Tainer, and E.D. Getzoff, Structural basis for endothelial nitric oxide synthase binding to calmodulin, EMBO J. 22 (2003), pp. 766–775. doi:https://doi.org/10.1093/emboj/cdg078.
- S. Francis, M. Blount, and J. Corbin, Mammalian cyclic nucleotide phosphodiesterases: Molecular mechanisms and physiological functions, Physiol. Rev. 91 (2011), pp. 651–690. doi:https://doi.org/10.1152/physrev.00030.2010.
- T. Keravis and C. Lugnier, Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: Benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments, Br. J. Pharmacol. 165 (2012), pp. 1288–1305. doi:https://doi.org/10.1111/j.1476-5381.2011.01729.x.
- J. Schlossmann and E. Schinner, cGMP becomes a drug target, Naunyn-Schmiedeberg’s Arch. Pharmacol. 385 (2012), pp. 243–252. doi:https://doi.org/10.1007/s00210-012-0730-6.
- Y. He, Y. Huang, C. Mai, H. Pan, H.-B. Luo, L. Liu, and Y. Xie, The immunomodulatory role of PDEs inhibitors in immune cells: Therapeutic implication in rheumatoid arthritis, Pharmacol. Res. 161 (2020), pp. 105134. doi:https://doi.org/10.1016/j.phrs.2020.105134.
- A. Schafer, D. Fraccarollo, L. Werner, and J. Bauersachs, Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure, Pharmacol. Res. 62 (2010), pp. 432–438. doi:https://doi.org/10.1016/j.phrs.2010.06.008.
- M. Yao, D.D. Roberts, and J.S. Isenberg, Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP, Pharmacol. Res. 63 (2011), pp. 13–22. doi:https://doi.org/10.1016/j.phrs.2010.10.014.
- M. Li, X. Sun, Z. Li, and Y. Liu, Inhibition of cGMP phosphodiesterase 5 suppresses serotonin signalling in pulmonary artery smooth muscles cells, Pharmacol. Res. 59 (2009), pp. 312–318. doi:https://doi.org/10.1016/j.phrs.2009.01.007.
- A. Rohini, N. Agrawal, C. Koyani, and R. Singh, Molecular targets and regulators of cardiac hypertrophy, Pharmacol. Res. 61 (2010), pp. 269–280. doi:https://doi.org/10.1016/j.phrs.2009.11.012.
- G. Baillie, G. Tejeda, and M. Kelly, Therapeutic targeting of 3ʹ, 5ʹ-cyclic nucleotide phosphodiesterases: Inhibition and beyond, Nat. Rev. Drug Discov. 18 (2019), pp. 770–796. doi:https://doi.org/10.1038/s41573-019-0033-4.
- A. Bhat, B. Ray, A.M. Mahalakshmi, S. Tuladhar, D. Nandakumar, M. Srinivasan, M.M. Essa, S.B. Chidambaram, G.J. Guillemin, and M.K. Sakharkar, Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders, Pharmacol. Res. 160 (2020), pp. 105078. doi:https://doi.org/10.1016/j.phrs.2020.105078.
- W.S. Ahmed, A.M. Geethakumari, and K.H. Biswas, Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors, Biomed. Pharmacother. 134 (2021), pp. 111128. doi:https://doi.org/10.1016/j.biopha.2020.111128.
- R.C. Kukreja, R. Ockaili, F. Salloum, C. Yin, J. Hawkins, A. Das, and L. Xi, Cardioprotection with phosphodiesterase-5 inhibition - a novel preconditioning strategy, J. Mol. Cell Cardiol. 36 (2004), pp. 165–173. doi:https://doi.org/10.1016/j.yjmcc.2003.11.001.
- R.C. Kukreja, F. Salloum, A. Das, R. Ockaili, C. Yin, Y.A. Bremer, P.W. Fisher, M. Wittkamp, J. Hawkins, E. Chou, A.K. Kukreja, X. Wang, V.R. Marwaha, and L. Xi, Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications, Vascul. Pharmacol. 42 (2005), pp. 219–232. doi:https://doi.org/10.1016/j.vph.2005.02.010.
- R.C. Kukreja, F.N. Salloum, A. Das, S. Koka, R.A. Ockaili, and L. Xi, Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases, Exp, Clin. Cardiol. 16 (2011), pp. e30–e35.
- R.C. Kukreja, Sildenafil and cardioprotection, Curr. Pharm. Des. 19 (2013), pp. 6842–6847. doi:https://doi.org/10.2174/138161281939131127110156.
- E. Giannetta, T. Feola, D. Gianfrilli, R. Pofi, V. Dall Armi, R. Badagliacca, F. Barbagallo, A. Lenzi, and A.M. Isidori, Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials, BMC Med. 12 (2014), pp. 185. doi:https://doi.org/10.1186/s12916-014-0185-3.
- S. Koka, L. Xi, and R.C. Kukreja, Chronic treatment with long-acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cyto skeletal rearrangement and redox regulation in type 2 diabetic hearts, Basic Res. Cardiol. 107 (2012), pp. 249. doi:https://doi.org/10.1007/s00395-012-0249-5.
- A. Varma, A. Das, N.N. Hoke, D.E. Durrant, F.N. Salloum, and R.C. Kukreja, Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice, PLoS One 7 (2012), pp. e45243. doi:https://doi.org/10.1371/journal.pone.0045243.
- S. Koka, A. Das, F.N. Salloum, and R.C. Kukreja, Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice, Free Radic. Biol. Med. 60 (2013), pp. 80–88. doi:https://doi.org/10.1016/j.freeradbiomed.2013.01.031.
- S. Koka, H.S. Aluri, L. Xi, E.J. Lesnefsky, and R.C. Kukreja, Chronic inhibition of phosphodiesterase5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: Potential role of NO/SIRT1/PGC-1alpha signaling, Am. J. Physiol. Heart Circ. Physiol. 306 (2014), pp. H1558–H1568. doi:https://doi.org/10.1152/ajpheart.00865.2013.
- K.L. Black, D. Yin, J.M. Ong, J. Hu, B.M. Konda, X. Wang, M.K. Ko, J.-A. Bayan, M.R. Sacapano, A. Espinoza, D.K. Irvin, and Y. Shu, PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model, Brain Res. 1230 (2008), pp. 290–302. doi:https://doi.org/10.1016/j.brainres.2008.06.122.
- L. Resnick, H. Rabinovitz, D. Binninger, M. Marchetti, and H. Weissbach, Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses, J. Drugs Dermatol. 8 (2009), pp. 29–32.
- A. Das, D. Durrant, C. Mitchell, E. Mayton, N.N. Hoke, F.N. Salloum, M.A. Park, I. Qureshi, R. Lee, P. Dent, and R.C. Kukreja, Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction, Proc. Natl. Acad. Sci. USA 107 (2010), pp. 18202–18207. doi:https://doi.org/10.1073/pnas.1006965107.
- T.K. Hamilton, N. Hu, K. Kolomitro, E.N. Bell, D.H. Maurice, C.H. Graham, and D.R. Siemens, Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer, World J. Urol. 31 (2013), pp. 325–330. doi:https://doi.org/10.1007/s00345-012-0848-7.
- L. Booth, J.L. Roberts, N. Cruickshanks, A. Conley, D.E. Durrant, A. Das, P.B. Fisher, R.C. Kukreja, S. Grant, A. Poklepovic, and P. Dent, Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/ genitourinary cancer cells, Mol. Pharmacol. 85 (2014), pp. 408–419. doi:https://doi.org/10.1124/mol.113.090043.
- L. Booth, J.L. Roberts, N. Cruickshanks, S. Grant, A. Poklepovic, and P. Dent, Regulation of OSU-03012 toxicityby ER stress proteins and ER stress-inducing drugs, Mol. Cancer Ther. 13 (2014), pp. 2384–2398. doi:https://doi.org/10.1158/1535-7163.MCT-14-0172.
- L. Booth, J.L. Roberts, N. Cruickshanks, S. Tavallai, T. Webb, P. Samuel, A. Conley, B. Binion, H.F. Young, A. Poklepovic, S. Spiegel, and P. Dent, PDE5 inhibitors enhance Celecoxib killing in multiple tumor types, J. Cell Physiol. 230 (2015), pp. 1115–1127. doi:https://doi.org/10.1002/jcp.24843.
- J.L. Roberts, L. Booth, A. Conley, N. Cruickshanks, M. Malkin, R.C. Kukreja, S. Grant, A. Poklepovic, and P. Dent, PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells, Cancer Biol. Ther. 15 (2014), pp. 758–767. doi:https://doi.org/10.4161/cbt.28553.
- A. Das, D. Durrant, F.N. Salloum, L. Xi, and R.C. Kukreja, PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer, Pharmacol. Ther. 147 (2015), pp. 12–21. doi:https://doi.org/10.1016/j.pharmthera.2014.10.003.
- L.J. Ignarro, P.A. Bush, G.M. Buga, K.S. Wood, J.M. Fukuto, and J. Rajfer, Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle, Biochem. Biophys. Res. Commun. 170 (1990), pp. 843–850. doi:https://doi.org/10.1016/0006-291x(90)92168-y.
- J. Rajfer, W.J. Aronson, P.A. Bush, F.J. Dorey, and L.J. Ignarro, Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission, N. Engl. J. Med. 326 (1992), pp. 90–94. doi:https://doi.org/10.1056/NEJM199201093260203.
- S.A. Huang and J.D. Lie, Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction, P T. 38 (2013), pp. 407–419.
- E. Bischoff, Potency, selectivity, and consequences of nonselectivity of PDE inhibition, Int. J. Impot. Res. 16 (2004), pp. S11–S14. doi:https://doi.org/10.1038/sj.ijir.3901208.
- T. Klein, M. Eltze, T. Grebe, A. Hatzelmann, and M. Komhoff, Celecoxib dilates Guinea- pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition, Cardiovasc. Res. 75 (2007), pp. 390–397. doi:https://doi.org/10.1016/j.cardiores.2007.02.026.
- J.M. Brophy, Celecoxib and cardiovascular risks, Exp. Opin. Drug Saf. 4 (2005), pp. 1005–1015. doi:https://doi.org/10.1517/14740338.4.6.1005.
- M. Abdel-Halim, H. Tinsley, A.B. Keeton, M. Weam, N.H. Atta, M.A. Hammam, A. Hefnawy, R.W. Hartmann, M. Engel, G.A. Piazza, and A.H. Abadi, Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors, Bioorg. Chem. 104 (2020), pp. 104322. doi:https://doi.org/10.1016/j.bioorg.2020.104322.
- M. Abdel-Halim, S. Sigler, N.A.S. Racheed, A. Hefnawy, R.K. Fathalla, M.A. Hammam, A. Maher, Y. Maxuitenko, A.B. Keeton, R.W. Hartmann, M. Engel, G.A. Piazza, and A.H. Abadi, From celecoxib to a novel class of phosphodiesterase 5 inhibitors: Trisubstituted pyrazolines as novel phosphodiesterase 5 inhibitors with extremely high potency and phosphodiesterase isozyme selectivity, J. Med. Chem. 64 (2021), pp. 4462–4477. doi:https://doi.org/10.1021/acs.jmedchem.0c01120.
- Chem 3D Pro8.0.3, Chem Draw Ultra Version 8.0.3, Cambridge Soft Corporation, USA. Software available at http://www.cambridgesoft.com
- S.A. Amin, S. Bhargava, N. Adhikari, S. Gayen, and T. Jha, Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: A predictive approach combining comparative validated multiple molecular modelling techniques, J. Biomol. Struct. Dyn. 36 (2018), pp. 590–608. doi:https://doi.org/10.1080/07391102.2017.1288659.
- S. Theodoridis, Classification: A tour of the classics, in Machine Learning A Bayesian and Optimization Perspective 2nd, Academic Press, United Kingdom, 2020, pp. 301–350. doi:https://doi.org/10.1016/B978-0-12-818803-3.00016-7.
- A. Baese-Meyer and V.J. Schmid, Statistical and syntactic pattern recognition, in Pattern Recognition and Signal Analysis in Medical Imaging 2nd, Academic Press, United Kingdom, 2014, pp. 151–196. doi:https://doi.org/10.1016/B978-0-12-409545-8.00006-6.
- Discovery Studio 3.0, Accelrys Inc, CA, USA, 2015. Software available at http://www.accelrys.com
- T. Fawcett, An introduction to ROC analysis, Pattern Recognit. Lett. 27 (2006), pp. 861–874. doi:https://doi.org/10.1016/j.patrec.2005.10.010.
- S.A. Amin, N. Adhikari, and T. Jha, Exploration of histone deacetylase 8 inhibitors through classification QSAR study: Part II, J. Mol. Struct. 1204 (2020), pp. 127529. doi:https://doi.org/10.1016/j.molstruc.2019.127529.
- L. Chen, Y. Li, Q. Zhao, H. Peng, and T. Hou, ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naïve Bayesian classification techniques, Mol. Pharmaceutics 8 (2011), pp. 889–900. doi:https://doi.org/10.1021/mp100465q.
- A. Zeileis, T. Hothorn, and K. Hornik, Model-based recursive partitioning, J. Comput. Graph. Stat. 17 (2008), pp. 492–514. doi:https://doi.org/10.1198/10618600SX319331.
- S. Landau and S. Barthel, Recursive partitioning, in International Encyclopedia of Education 3rd, Elsevier, United Kingdom, 2010, pp. 383–389. doi:https://doi.org/10.1016/B978-0-08-044894-7.01314-2.
- C. Strobl, J. Malley, and G. Tutz, An introduction to recursive partitioning: Rationale, application, and characteristics of classification and regression trees, bagging and random forests, Psychol. Methods 14 (2009), pp. 323–348. doi:https://doi.org/10.1037/a0016973.
- P.M. Sivakumar, S.K. Geetha Babu, and D. Mukesh, QSAR studies on chalcones and flavonoids as anti-tuberculosis agents using genetic function approximation (GFA) method, Chem. Pharm. Bull. 55 (2007), pp. 44–49. doi:https://doi.org/10.1248/cpb.55.44.
- J. Bajorath, S. Kearnes, W.P. Walters, N.A. Meanwell, G.I. Georg, and S. Wang, Artificial intelligence in drug discovery: Into the great wide open, J. Med. Chem. 63 (2020), pp. 8651–8652. doi:https://doi.org/10.1021/acs.jmedchem.0c01077.
- R. Qin, H. Wang, and A. Yan, Classification and QSAR models of leukotriene A4 hydrolase (LTA4H) inhibitors by machine learning methods, SAR QSAR Environ. Res. 32 (2021), pp. 411–431. doi:https://doi.org/10.1080/1062936X.2021.1910862.
- Y. Wu, D. Huo, G. Chen, and A. Yan, SAR and QSAR research on tyrosinase inhibitors using machine learning methods, SAR QSAR Environ. Res. 32 (2021), pp. 85–110. doi:https://doi.org/10.1080/1062936X.2020.1862297.
- F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer, R. Weiss, V. Dubourg, J. Vanderplas, A. Passos, D. Cournapeau, M. Brucher, M. Perrot, and E. Duchesnay, Scikit-learn: Machine learning in Python, JMLR 12 (2011), pp. 2825–2830. Available at https://scikit-learn.org/stable/index.html
- A.O. Aptula, N.G. Jeliazkova, T.W. Schultz, and M.T.D. Cronin, The better predictive model: High q2 for the training set or low root mean square error of prediction for the test set? QSAR Comb. Sci. 24 (2005), pp. 385–396. doi:https://doi.org/10.1002/qsar.200430909.
- G. Gini, F. Zanoli, A. Gamba, G. Raitano, and E. Benfenati, Could deep learning in neural networks improve the QSAR models? SAR QSAR Environ. Res. 30 (2019), pp. 617–642. doi:https://doi.org/10.1080/1062936X.2019.1650827.
- V. Solov’ev, D. Baulin, and A. Tsivadze, Design of phosphoryl containing podands with Li+/Na+ selectivity using machine learning, SAR QSAR Environ. Res. 32 (2021), pp. 521–539. doi:https://doi.org/10.1080/1062936X.2021.1929462.
- O. Spjuth, J. Frid, and A. Hellander, The machine learning life cycle and the cloud: Implications for drug discovery, Expert Opin. Drug Discov. 31 (2021), pp. 1–9. doi:https://doi.org/10.1080/17460441.2021.1932812.
- J.A. Castillo-Garit, S.J. Barigye, H. Pham-the, V. Pérez-Doñate, F. Torrens, and F. Pérez-Giménez, Computational identification of chemical compounds with potential anti-Chagas activity using a classification tree, SAR QSAR Environ. Res. 32 (2021), pp. 71–83. doi:https://doi.org/10.1080/1062936X.2020.1863857.
- K. Ghosh, B. Bhardwaj, S.A. Amin, T. Jha, and S. Gayen, Identification of structural fingerprints for ABCG2 inhibition by using Monte Carlo optimization, Bayesian classification, and structural and physicochemical interpretation (SPCI) analysis, SAR QSAR Environ. Res. 31 (2020), pp. 439–455. doi:https://doi.org/10.1080/1062936X.2020.1771769.
- D.G. Madhukar, N. Subbarao, and N. Subbarao, Development and rigorous validation of antimalarial predictive models using machine learning approaches, SAR QSAR Environ. Res. 30 (2019), pp. 543–560. doi:https://doi.org/10.1080/1062936X.2019.1635526.
- T.B. Kimber, Y. Chen, and A. Volkamer, Deep learning in virtual screening: Recent applications and developments, Int. J. Mol. Sci. 22 (2021), pp. 4435. doi:https://doi.org/10.3390/ijms22094435.
- J. Devillers, Methods for building QSARs, Methods Mol. Biol. 930 (2013), pp. 3–27. doi:https://doi.org/10.1007/978-1-62703-059-5_1.